Sanofi Net Worth

The estimated Net Worth of Sanofi is at least $869 Million dollars as of 14 September 2021. Sanofi Sanofi owns over 71,983,597 units of Inozyme Pharma stock worth over $394,230,442 and over the last 11 years Sanofi sold INZY stock worth over $474,746,129.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Sanofi Sanofi INZY stock SEC Form 4 insiders trading

Sanofi has made over 63 trades of the Inozyme Pharma stock since 2014, according to the Form 4 filled with the SEC. Most recently Sanofi bought 71,983,597 units of INZY stock worth $2,735,376,686 on 14 September 2021.

The largest trade Sanofi's ever made was buying 71,983,597 units of Inozyme Pharma stock on 14 September 2021 worth over $2,735,376,686. On average, Sanofi trades about 1,737,835 units every 43 days since 2014. As of 14 September 2021 Sanofi still owns at least 75,668,031 units of Inozyme Pharma stock.

You can see the complete history of Sanofi Sanofi stock trades at the bottom of the page.

What's Sanofi Sanofi's mailing address?

Sanofi's mailing address filed with the SEC is 54 Rue La Boétie, 75008 Paris, France.

Insiders trading at Inozyme Pharma

Over the last 4 years, insiders at Inozyme Pharma have traded over $0 worth of Inozyme Pharma stock and bought 11,149,230 units worth $104,131,475 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, Inozyme Pharma executives and independent directors trade stock every 46 days with the average trade being worth of $2,019,505. The most recent stock trade was executed by Douglas A Treco on 1 April 2024, trading 25,000 units of INZY stock currently worth $130,250.

What does Inozyme Pharma do?

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Complete history of Sanofi Sanofi stock trades at Alnylam Pharmaceuticals Inc, MyoKardia, Regeneron Pharmaceuticals, Regulus Therapeutics Inc, Voyager Therapeutics Inc, Telesis Bio Inc, Fulcrum Therapeutics Inc und Inozyme Pharma

Inozyme Pharma executives and stock owners

Inozyme Pharma executives and other stock owners filed with the SEC include:

• Axel Bolte M.B.A., M.Sc.,
  Co-Founder, Pres, CEO & Director
• Axel Bolte,
  Co-Founder, Pres, CEO & Director
• Henric Bjorn Bjarke,
  Sr. VP & COO
• Dr. David Thompson M.A., M.S., Ph.D.,
  Chief Devel. Officer & Member of Scientific Advisory Board
• Gayle Gironda,
  Sr. VP of HR
• Stefan Riley,
  Director of Investor Relations
• Stephen J. DiPalma M.B.A.,
  Interim Chief Financial Officer
• Dr. Kevin B. Johnson M.B.A., Ph.D., MBA.,
  Sr. VP of Regulatory Affairs
• Dr. Pedro Huertas,
  Sr. VP & Chief Medical Officer
• Dr. David Thompson Ph.D.,
  Sr. Advisor
• Tara Greene,
  VP of Quality & Compliance
• Brian Luque,
  Director of Investor Relations
• Dr. Yves Sabbagh,
  Sr. VP & Chief Scientific Officer
• Stephen Basso M.B.A.,
  Sr. VP of Fin.
• Steven J. Jungles,
  Sr. VP & Chief Technical Operations Officer
• Pharmaceuticals, Inc. Alexion,
  10% owner
• Joseph Schlessinger,
  10% owner
• Bio Venture Partners Fund I...,
  
• Capital Partners Iii, Llc L...,
  
• Enterprise Associates 15, L...,
  
• Forest Baskett,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Steven J Jungles,
  SVP, CTO
• Sanjay Subramanian,
  SVP, CFO
• Douglas A Treco,
  CEO
• Martin Edwards,
  
• Sarah M Bhagat,
  
• Scott D Sandell,
  10% owner
• Peter W. Sonsini,
  10% owner
• Capital Management, L.P.Kol...,
  
• Springs Capital Management ...,
  
• Sanofi,
  10% owner
• Holdings A/S Novo,
  10% owner
• Lynne Marie Sullivan,
  
• Reinaldo M Diaz,
  
• Henric Bjorn Bjarke,
  SVP, COO
• Edward T Mathers,
  
• Venture Partners X, L.P.Sof...,
  
• Joshua Makower,
  10% owner
• Stephen Basso,
  SVP Finance (PFO)
• Deborah Wenkert,
  SVP, CMO
• Stephen J. Di Palma,
  Interim CFO
• Pharma, Inc. Inozyme,
  Director
• Axel Bolte,
  
• Matthew Winton,
  COO
• Robert Lorne Hopfner,